Last reviewed · How we verify
Esomeprazole Mg
At a glance
| Generic name | Esomeprazole Mg |
|---|---|
| Also known as | Nexium |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (PHASE4)
- A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks (NA)
- A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer (PHASE3)
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
- Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU
- Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection (NA)
- Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1) (PHASE4)
- Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Esomeprazole Mg CI brief — competitive landscape report
- Esomeprazole Mg updates RSS · CI watch RSS
- AstraZeneca portfolio CI